Synformulas GmbH

This is a leading global probiotics company focusing on smart bacteria for treating patients with allergies and gastrointestinal diseases, having achieved a breakthrough in irritable bowel syndrome (IBS) treatment: in two independent studies, its patented bacterial strain MIMBb75 showed a significant effect on this widespread disease, and it is the most used bacterial strain in Europe for this indication. To develop future-oriented products with clinically proven efficacy, the company employs an efficient R&D team and cooperates with a broad network of internationally recognized researchers and universities; with a strong sales force visiting doctors and pharmacies across Western Europe, it reached high double-digit million revenue in 2020 and continues seeking new distribution and licensing partnerships.